Trials / Completed
CompletedNCT03774056
A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.
A Phase I Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients With Metastatic Castration-Resistant Prostate Cancer.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Hinova Pharmaceuticals Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I study evaluating tolerability, pharmacokinetics, and preliminary efficacy of HC-1119 in patients with metastatic castration-resistant prostate cancer. The study objective is to study the tolerability, safety, and dose-limiting toxicities (DLT) of HC-1119 in patients with mCRPC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HC-1119 | oral |
Timeline
- Start date
- 2017-02-10
- Primary completion
- 2018-09-26
- Completion
- 2019-08-28
- First posted
- 2018-12-12
- Last updated
- 2020-11-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03774056. Inclusion in this directory is not an endorsement.